Treatment of Symptomatic Lumbar Internal Disc Disruption (IDD) With the Biostat® System

This study has been terminated.
(Stopped prior to last subject's last extended follow-up visit (78 weeks) due to lack of efficacy at the primary study endpoint (26 weeks))
Sponsor:
Information provided by (Responsible Party):
Spinal Restoration, Inc.
ClinicalTrials.gov Identifier:
NCT01011816
First received: November 9, 2009
Last updated: May 5, 2014
Last verified: May 2014
  Purpose

The purpose of this investigation is to establish the safety and efficacy of the Biostat System when used for treatment of chronic low back (lumbar) pain due to symptomatic internal disc disruptions (IDD) by comparing safety and efficacy outcome measures between one group receiving BIOSTAT BIOLOGX® Fibrin Sealant through the Biostat® Delivery Device and another group receiving a preservative-free normal saline control delivered with the Biostat Delivery Device.


Condition Intervention Phase
Back Pain
Chronic Low Back Pain
Internal Disc Disruption
Degenerative Disc Disease
Biological: BIOSTAT BIOLOGX
Drug: Saline
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Blinded, Saline-Controlled Trial of Resorbable Biologic Disc Augmentation for Treatment of Symptomatic Lumbar Internal Disc Disruption (IDD) With the Biostat® System

Resource links provided by NLM:


Further study details as provided by Spinal Restoration, Inc.:

Primary Outcome Measures:
  • Subject Composite Success [ Time Frame: 26 weeks ] [ Designated as safety issue: Yes ]
    Subject success based on a composite of minimum 30% decrease in low back pain, 30% improvement in function, maintenance of neurological status, no secondary interventions, and no serious adverse events.


Secondary Outcome Measures:
  • Visual Analog Scale for Low Back Pain [ Time Frame: 26-weeks ] [ Designated as safety issue: No ]

    Percent of subjects achieving a minimum 30% decrease in pain from baseline.

    The visual analog scale is a horizontal 100 mm line anchored on the left with the words "No Pain" and on the right with the words "Worst Possible Pain". Scores were obtained by measuring the distance in millimeters from the left origin of the line (0) to the point indicated with a slash placed by the subject to indicate the subject's level of low back pain experienced over the last week.


  • Roland-Morris Disability Questionnaire Score [ Time Frame: 26-weeks ] [ Designated as safety issue: No ]

    Percent of subjects achieving a minimum 30% decrease in Roland-Morris Disability Questionnaire score

    The Roland-Morris Disability Questionnaire is a widely studied and frequently used instrument for the assessment of function and disability related to low back pain. The questionnaire consists of 24 statements related to how a subject's back condition affects various activities of daily living. Subjects marked whether the statement either applied to them or did not apply at the time they responded to the statements. The score is the total number of questions with which the subject agreed. A higher score indicates less function and greater disability.



Enrollment: 220
Study Start Date: March 2010
Study Completion Date: May 2013
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BIOSTAT BIOLOGX
One injection of up to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant into a single lumbar intervertebral disc
Biological: BIOSTAT BIOLOGX
One injection of up to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant into a single lumbar intervertebral disc using the Biostat Delivery Device
Other Name: Fibrin Sealant
Placebo Comparator: Saline
One injection of up to 4 mL of saline solution into a single lumbar intervertebral disc
Drug: Saline
One injection of up to 4 mL of saline using the Biostat Delivery Device
Other Name: 0.9% w/v Sodium Chloride Injection, USP

Detailed Description:

The Biostat System is a combination product combining a resorbable biologic product with a delivery device system used to prepare and insert the biologic material into a lumbar intervertebral disc.

Symptomatic IDD is defined as a painful disruption of the internal architecture of a lumbar intervertebral disc, which appears as fissures, cracks or tears within the internal structures of the disc. Pain arising from a lumbar disc may not only be perceived as pain located in the low back (axial pain) but also as somatic referred pain involving the posterior hips, buttocks, lateral hips, groin, or posterior thighs.

The diagnosis of symptomatic IDD cannot currently be made on the basis of imaging studies, physical examination, or symptoms alone, and is best established with meticulously conducted disc provocation studies (provocation discography) that include pressure manometry and identification of an adjacent normal disc.

This treatment and study are not designed for patients exhibiting other potential sources of chronic low back pain such as more advanced degenerative disc disease with significant loss of disc height (>33%), spinal stenosis, or spondylolisthesis (see Eligibility Criteria).

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18 or older and skeletally mature.
  • Voluntarily signs the subject informed consent form and agrees to the release of medical information for purposes of this study (HIPAA authorization).
  • Physically and mentally able to comply with the protocol, including ability to read and complete required forms, and willing and able to adhere to the follow-up requirements of the protocol.
  • Chronic low back pain for at least 6 months.
  • Pretreatment baseline low back pain of at least 40 mm on a 100 mm visual analog scale.
  • Pretreatment baseline Roland-Morris Disability Questionnaire score of at least 9 on the 24-point questionnaire.
  • Leg pain, if present, is of nonradicular origin, i.e., not due to stimulation of nerve roots or dorsal root ganglion of a spinal nerve by compressive forces.
  • Leg pain, if present, does not extend below the knee and is no greater than 50% of low back pain as measured on a visual analog scale. If bilateral leg pain, the worst leg pain is no greater than 50% of low back pain.
  • Low back pain unresponsive to at least 3 months of nonoperative care, which may include bed rest, antiinflammatory and analgesic medications, chiropractic manipulations, acupuncture, massage, physical therapy or home-directed lumbar exercise program.
  • Diagnostic medial branch block or facet joint injection between 18 months and 2 weeks prior to the study procedure indicates no facet joint involvement.
  • Diagnosis of symptomatic lumbar (L1-L2 - L5-S1) internal disc disruption (IDD), which requires confirmation of discogenic pain at one or two contiguous levels through positive provocation discography performed between 18 months and 2 weeks prior to the study procedure using pressure manometry and identification of an adjacent nonpainful disc. The disc provocation studies must precisely demonstrate concordant pain (<50 psi above opening pressure) and must demonstrate a fissure(s) in the outer one-third of the posterior or lateral anulus.

Exclusion Criteria:

  • Cauda equina syndrome.
  • Active malignancy or tumor as source of symptoms.
  • Current infection or prior history of spinal infection (e.g., discitis, septic arthritis, epidural abscess) or an active systemic infection.
  • Previous lumbar spine surgery.
  • Evidence of prior lumbar vertebral body fracture.
  • Disc bulge/protrusion or focal herniation at the symptomatic level(s) > 4 mm.
  • Presence of disc extrusion or sequestration.
  • Leg pain is greater than 50% of low back pain as measured on a visual analog scale.
  • Leg pain that extends below the knee.
  • Lumbar intervertebral foramen stenosis at the affected level(s) resulting in significant spinal nerve root compression (effacement of the majority of periganglion fat and loss of CSF signal around the nerve rootlets).
  • Symptomatic central vertebral canal stenosis or absolute sagittal vertebral canal diameter < 9mm.
  • Loss of disc space height at the symptomatic level(s) greater than one-third of an adjacent normal disc (or of the expected height in the case of an L5-S1 disc).
  • Spondylolisthesis (> Grade 1) with or without spondylolysis at the symptomatic level(s).
  • Lumbar spondylitis or other undifferentiated spondyloarthropathy.
  • Dynamic instability at the symptomatic level(s) on lumbar flexion-extension radiographs indicated by >4.5 mm of translation or angular motion >15° at L1-L2, L2-L3, or L3-L4; >20° at L4-L5; or >25° at L5-S1.
  • Diagnostic medial branch block or facet joint injection indicate facet joint involvement.
  • Diagnostic sacroiliac injection indicates sacroiliac joint involvement for those patients with pain in the sacral region.
  • Sustained relief (>3 months) of low back pain obtained with epidural injection of corticosteroids.
  • Symptomatic involvement of more than two lumbar disc levels determined from discography.
  • Neurological examination shows findings of radiculopathy or a significant underlying neurological condition (motor strength <4; sensory assessment abnormal; or reflexes absent or hyperactive with clonus).
  • Prior thermal intradiscal procedure (e.g., intradiscal electrothermal therapy, intradiscal radiofrequency thermocoagulation).
  • Any lumbar intradiscal injection procedure other than discography (e.g., injection of corticosteroids, methylene blue, dextrose, or glucosamine and chondroitin sulfate).
  • Significant systemic disease, including unstable angina, autoimmune disease, rheumatoid arthritis, and muscular dystrophy.
  • Congenital or acquired coagulopathy or thrombocytopenia; or currently taking anticoagulant, antineoplastic, antiplatelet, or thrombocytopenia-inducing medications; or undergoing radiation therapy.
  • History of unexplained, easy, or persistent bruising or bleeding, bleeding from the gums, or bleeding problems experienced in previous surgical procedures.
  • Aspirin or aspirin-containing medication taken ≤ 7 days prior to the procedure.
  • Known or suspected hypersensitivity or allergy to drugs or components of the fibrin sealant (fibrinogen, thrombin, aprotinin, CaCl2) used in the procedure.
  • History of, or current psychiatric or psychological condition, or substance or alcohol abuse that would potentially interfere with the subject's participation in the study.
  • Ongoing or previous participation in another drug or device clinical study within the previous 2 months.
  • Subject known to be pregnant or nursing at time of enrollment or with plans to become pregnant within the planned length of follow-up.
  • Body habitus precludes adequate fluoroscopic visualization for the procedure or the procedure is physically impossible using the device.
  • Concomitant conditions requiring daily oral steroid use for more than 30 days in the preceding 90 days.
  • Pending litigation against a health care professional, except where required by the insurer as a condition of coverage, personal injury compensation or litigation claims.
  • Prisoner or active military personnel who would not be available for follow-up.
  • Presence of ferromagnetic implants that would disallow MRI of the symptomatic disc(s).
  • Active or pending workers' compensation claims.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01011816

Locations
United States, Alabama
Alabama Clinical Therapeutics, LLC
Birmingham, Alabama, United States, 35235
United States, Arizona
HOPE Research Institute
Phoenix, Arizona, United States, 85050
United States, California
Pain Control Associates of San Diego
Chula Vista, California, United States, 91914
Napa Pain Institute
Napa, California, United States, 94559
California Spine Diagnostics
San Francisco, California, United States, 94115
The Spine Institute
Santa Monica, California, United States, 90403
United States, Florida
The Pain Institute, Inc
Merritt Island, Florida, United States, 32953
United States, Illinois
Millennium Pain Center
Bloomington, Illinois, United States, 61701
United States, Maryland
The Spine Center
Baltimore, Maryland, United States, 21211
United States, Minnesota
Medical Advanced Pain Specialists Applied Research Center
Edina, Minnesota, United States, 55435
United States, Mississippi
NewSouth NeuroSpine Pain Center
Flowood, Mississippi, United States, 39232
United States, North Carolina
OrthoCarolina Spine Center
Charlotte, North Carolina, United States, 28207
United States, Ohio
Cleveland Clinic
Cleveland, Ohio, United States, 44195
OrthoNeuro, Inc.
New Albany, Ohio, United States, 43054
United States, Pennsylvania
Allegheny Pain Management
Altoona, Pennsylvania, United States, 16602
Orthopaedic & Spine Specialists
York, Pennsylvania, United States, 17402
United States, Texas
Spine Specialists PA
Tyler, Texas, United States, 75701
United States, Virginia
Virginia Spine Research Institute
Richmond, Virginia, United States, 23235
Advanced Pain Management
Virginia Beach, Virginia, United States, 23454
United States, Washington
Bellingham Spine Pain Specialists PS
Bellingham, Washington, United States, 98226
Sponsors and Collaborators
Spinal Restoration, Inc.
Investigators
Principal Investigator: Kevin J Pauza, MD Spine Specialists PA
  More Information

Publications:
Responsible Party: Spinal Restoration, Inc.
ClinicalTrials.gov Identifier: NCT01011816     History of Changes
Other Study ID Numbers: SR-BX01-2007
Study First Received: November 9, 2009
Results First Received: April 2, 2014
Last Updated: May 5, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Spinal Restoration, Inc.:
intervertebral disk

Additional relevant MeSH terms:
Back Pain
Low Back Pain
Intervertebral Disc Degeneration
Pain
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Spinal Diseases
Bone Diseases
Musculoskeletal Diseases
Fibrin Tissue Adhesive
Hemostatics
Coagulants
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on October 19, 2014